Persius/hicric huggingface dataset:
Terconazole drug interactions

# Drug Interactions
TERAZOL 7 (terconazole) Vaginal Cream 0.4% and TERAZOL 3 (terconazole) Vaginal Suppositories 80 mg
The therapeutic effect of these products is not affected by oral contraceptive usage.
TERAZOL 3 (terconazole) Vaginal Cream 0.8%
The levels of estradiol (E2) and progesterone did not differ significantly when 0.8% terconazole vaginal cream was administered to healthy female volunteers established on a low dose oral contraceptive.
The Cancer Council Queensland

# Overview
The Cancer Council Queensland is Queensland's foremost anti-cancer organisation. It is an independent, community-based charity and is not government funded. The Cancer Council aims to reduce the impact of cancer--particularly the suffering it causes--and ultimately to eliminate the disease, by raising funds to advance cancer research; improve cancer treatment; support people with cancer, their family and friends; and increase community awareness of cancer, its prevention and early detection.  The Cancer Council Queensland is a member of The Cancer Council Australia.
The Cancer Council Queensland is the largest non-government provider of cancer research funds in the state. It has a dedicated research centre, the Viertel Centre for Research in Cancer Control, which includes an Epidemiology Unit, a Psycho-Oncology Research Unit, and the Queensland Cancer Registry.

# Services
The Fund offers a range of support services to help ease the burden on Queenslanders with cancer and their families. These services are tailored to meet the needs of people with various types of cancer and involve practical assistance such as financial aid, equipment loan and a wig and turban service. The Cancer Council Queensland operates The Cancer Council Helpline to provide information and support at the cost of a local call.
During 2005 The Cancer Council Helpline received calls from more than 50,000 Queenslanders, while the Cancer Counselling Service provided confidential telephone counselling to more than 600 clients. Through the support of the community, the Fund is also able to contribute funding for treatment facilities and equipment across the state, provide accommodation facilities for patients receiving treatment in three cities across the state, and educate the community on the prevention and early detection of cancer.

# Fundraising
Because it does not receive government funding, The Cancer Council Queensland receives donations from the Queensland public, through bequests and fundraising events such as Daffodil Day, Australia's Biggest Morning Tea and Relay For Life.

# History
The Cancer Council Queensland was established in 1961 as the Queensland Cancer Fund. It's original purpose was to purchase medical equipment for the Queensland Radium Institute, a part of the state health department.
On May 1, 2007, the Queensland Cancer Fund was renamed to The Cancer Council Queensland and adopted the daffodil, the international symbol of hope, as its logo. It replaced the caduceus, a staff with an intwined snake, which was its original logo.
The name change more closely aligned the organisation with other states and territories of Australia, all of which have an anti-cancer organisation named The Cancer Council, all of which are members of The Cancer Council Australia.

# External link
- Official site
The heart in multiple myeloma

# Histopathological Findings
Image courtesy of Professor Peter Anderson DVM PhD and published with permission  PEIR, University of Alabama at Birmingham, Department of Pathology
- HEART: Thrombotic Nonbacterial Endocarditis Infected: Micro low mag H&E vegetation with no valve seen large number of superficial neutrophils is evidence of infection case of multiple myeloma
- HEART: Thrombotic Nonbacterial Endocarditis Infected: Gross natural color aortic valve vegetations excellent example case of multiple myeloma
- HEART: Thrombotic Nonbacterial Endocarditis Infected: Gross natural color mitral valve lesion excellent example case of multiple myeloma
- HEART: Thrombotic Nonbacterial Endocarditis Infected: Gross natural color pulmonary valve excellent example case of multiple myeloma
- HEART: Thrombotic Nonbacterial Endocarditis Infected: Gross natural color excellent example case of multiple myeloma
The heart in Wilson's disease
Assistant Editor-in-Chief: Brian Blank

# Overview
Wilson's disease affects multiple organ systems including the cardiovascular system.  Cardiovascular complications of Wilson's disease include cardiomyopathy, heart failure and cardiac arrhythmias.

# Pathophysiology
Accumulation of copper in myocardial tissue is postulated to be the underlying mechanism of disease in the patient with Wilson's disease. At autopsy myocardial copper concentrations in patients with Wilson's disease ranged from 2.28 gm / g to 1,428 gm / g.   It has been speculated that the wide range in copper concentrations could result from variable responses to copper chelation therapy.  Increased copper levels were not correlated with the severity of the myocardial lesions which raises a question as to the role of the patient's autoimmune response to the copper deposition.  Copper levels were evaluated within myocardial tissue.

# Clinical Findings
Several patterns of cardiovascular involvement have been identified among patients with Wilsons disease. Cardiovascular involvement was not present at the time of study entry in one study which followed 54 patients prospectively for 10 years:

## Arrhythmias
More than 50% of patients developed electrocardiographic (ECG) abnormalities. These abnormalities included:
- Left ventricular hypertrophy
- Biventricular hypertrophy
- Early repolarization
- ST depression and T inversion
- Premature atrial contractions
- Premature ventricular contractions
- Atrial fibrillation
- Sinoatrial block
- Mobitz type 1 atrioventricular block
Wilson's Disease is often associated with resting tremors. Therefore, before diagnosing atrial fibrillation or other ECG abnormalities, tremor artifacts on the ECG should also be excluded in the patient with Wilson's disease.

## Cardiomyopathy
On biopsy and or pathologic evaluation the following abnormalities can be present:
- Interstitial fibrosis
- Sclerosis of the intramyocardial small vessels
- Perivascular myocarditis

## Autonomic Dysfunction
As a manifestation of autonomic dysfunction, there can be an abnormal response to the Valsalva maneuver.

# Complications from Cardiovascular Involvement
In some patients with Wilson's disease ventricular fibrillation and complications of progressive heart failure due to a cardiomyopathy can result in death.
The Michael J. Fox Foundation
The Michael J. Fox Foundation for Parkinson's Research is the largest private funder in the U.S. of medical research into Parkinson's disease.
The foundation was established by actor Michael J. Fox in May 2000, shortly after announcing his retirement from the ABC television show Spin City. In 1998 Fox publicly disclosed that he had been diagnosed with young-onset Parkinson's seven years earlier.
The Foundation is dedicated to ensuring the development of a cure for Parkinson's disease within this decade through an aggressively funded research agenda. Its strong focus is on "translational" research -- that is, the work of translating basic science discoveries into practical treatments with potential to benefit the estimated six million people living with Parkinson's today.
Enormous progress toward finding a cure has been made on many neurological fronts, and scientists' understanding of the brain and how disease affects continues to increase dramatically. The Foundation drives progress by awarding grants to ensure that the most promising research avenues are thoroughly funded, explored and carried forward toward their ultimate payoff -- new therapies and a cure.
To date the Foundation has funded more than $90 million in research directly or through partnerships      .

# Team Fox
Team Fox for Parkinson's Research is the foundations grassroots community project raising funds and awareness for Parkinsons research.
Tobacco industry in Argentina
The tobacco industry of Argentina produced 157,294 tonnes of tobacco in the 2003/2004 harvest, of which the larger part (93,327 tonnes) were exported. The planted area was 831.75 km2, of which 776 were harvested.
The tobacco industry is dominated by two transnational companies: Massalin Particulares S.A. (a subsidiary of Philip Morris, which sells the Marlboro brand, and which in turn is associated with Tabacos Norte S.A.) and Nobleza Piccardo (a subsidiary of British American Tobacco, which sells international brands such as Lucky Strike, Viceroy and Camel, as well as national ones like Jockey and Derby).
Tobacco producers are concentrated in the north of the country. The provinces of Jujuy and Salta (in the north-west), and Misiones (in the north-eastern Mesopotamia), are the leading ones, with over 45,000 tonnes/year each. The other tobacco-producing provinces are Tucuman, Corrientes, Chaco and Catamarca.
Tobacco plays an important role in the economy of the producing areas, which are comparatively poor provinces. The Argentine tobacco industry employs 500,000 people, about half of them directly involved in the planting and harvesting, only about 2% in the manufacturing of the derived products, and the rest in distribution and sales. Therefore, despite the fact that the consequences of smoking are a major health issue in Argentina, the national government supports the producers by means of a Tobacco Special Fund (Fondo Especial del Tabaco, FET), which consists in a subsidy plus easier access to credit in order to modernize the industry.
Toronto East General Hospital
Toronto East General Hospital is a teaching hospital located in Toronto, Ontario, in the former borough of East York.
The hospital has 382 acute care beds, as well as 13 rehabilitation and 75 complex continuing care beds.  In 2006/07, the hospital had over 60,000 emergency room visits and more than 19,000 in-patient admissions.
Approximately 3,500 babies were delivered during this period at the hospital's Maternal Newborn and Child Health Centre, which provides Level II Maternity and Neonatal Care and is a regional paediatric centre of the Child Health Network of Toronto.
The hospital's chief of staff is Dr. Alfio Meschino and its president and CEO is Rob Devitt.

# Services
- Ambulatory and Community Services
- Complex Continuing Care and Short-Term Rehabilitation
- Emergency
- Maternal/Newborn/Child
- Medicine
- Mental Health
- Pharmacy
- Surgery
- Diagnostic Imaging
- Laboratory Medicine
Tourette Syndrome Association
The Tourette Syndrome Association (TSA), based in Bayside, New York, United States, is a non-profit voluntary organization and the only national health-related organization serving people with Tourette syndrome.  It was founded in 1972 by a group of parents of children with Tourette syndrome, along with Arthur K. Shapiro and his wife, Elaine.
The TSA's mission is to identify the cause of, find the cure for and control the effects of Tourette Syndrome.  It has 35 U.S. chapters, 300 support groups, and international contacts around the world.
The TSA "has been the major driving force in scientific and clinical progress relevant to TS", using its resources to encourage research and scientific initiatives, and working tirelessly to promote information about TS. The TSA has worked for recognition of Tourette syndrome as an organic disorder, lobbying the public, the government, and physicians.  They have become adept at winning grants and shaping media treatment of the condition.  Since its inception, research spurred by the TSA has grown in volume and sophistication, including controlled treatment studies and studies of pathophysiology and etiology.  Many new research findings are the direct result of the TSA's "active facilitation of large collaborative research consortia in genetics, neuro-imaging, clinical trials, and the behavioral sciences", and their "concerted effort to identify current research advances, disseminate them among the scientific and clinical communities, and establish networks of basic and clinical scientists from all over the world".
In 2005 HBO and the Tourette Syndrome Association produced an Emmy Award-winning documentary film, I Have Tourette's But Tourette's Doesn't Have Me.

# Notes
-  Jump up to: 1.0 1.1 Pagewise, Inc.  Tourette syndrome.  Retrieved on 29 June 2006.
-  Tourette Syndrome Association. About TSA.  Retrieved on 16 July 2006.
-  Jump up to: 3.0 3.1 Walkup, JT, Mink, JW, Hollenback, PJ, (eds).  Advances in Neurology, Vol. 99, Tourette Syndrome.  Lippincott, Williams & Wilkins, Philadelphia, PA, 2006. p. xv.
-  Cohen DJ, Jankovic J, Goetz CG, (eds). Advances in Neurology, Vol. 85, Tourette Syndrome. Lippincott, Williams & Wilkins, Philadelphia, PA, 2001., pp. xviixviii.
-  Black, KJ. Tourette Syndrome and Other Tic Disorders.  eMedicine (March 22, 2006).  Retrieved on 27 June 2006.
Transient neurological attack
In contract, for focal symptoms, see Transient ischemic attack.

# Etiology
14% have acute stroke (diffusion-weighted imaging positive)

# Symptoms
The most common symptoms are:
- Loss in consciousness (including syncope) or less commonly a decrease in consciousness
- Dizziness (not including vertigo)
- Amnesia
- Unsteadiness
Witness observations can add to diagnostic accuracy, especially in distinguishing epilepsy from syncope. Witnesses are less able to help distinguish syncope from psychogenic nonepileptic seizures (PNES).

# Prognosis
Atypical neurologic symptoms increase the risk of stroke.
In a cohort study of 6062 adults about 5% had a TNA over 10 years found rates of subsequent stroke and dementia were increased depending on type of transient neurological attack (see table).
Among nonfocal symptoms:
- Vision disorders such as blurring or dimming may portend a subsequent stroke. If the patient truly has symptoms in both eyes, the patient's symptoms should be a homonymous hemianopsia visual field defect.. If the symptoms are just in one eye, then the patient may have disease of the carotid or retinal artery causing amaurosis fugax.
- Transient global amnesia is not a risk factor subsequent stroke.
- Nonrotary dizziness may or may not be a risk factor for subsequent stroke.
Transvaginal oocyte retrieval
Transvaginal oocyte retrieval or simply oocyte retrieval (OCR) is a technique used in in vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body. It is commonly known as "egg collection".

# Procedure
The technique mostly succeeds an ovarian stimulation, where multiple oocytes are manipulated to mature. The retrieval is performed with a needle, piercing through the vaginal wall. It is guided by ultrasound to reach the ovaries, where it can aspirate follicular material. This material can then be purified of ova.
The process takes about 20 minutes and is usually done under conscious sedation or general anesthesia.

# Transvaginal ovum retrieval
Transvaginal oocyte retrieval can be called transvaginal ovum retrieval if the oocytes have matured into ova. This is normally the case in IVF.
Trifluridine clinical studies

# Clinical Studies
During a controlled multicenter clinical trial, 92 of 97 (95%) patients (78 of 81 with dendritic and 14 of 16 with geographic ulcers) responded to therapy with VIROPTIC as evidenced by complete corneal re-epithelialization within the 14-day therapy period. Fifty-six of 75 (75%) patients (49 of 58 with dendritic and 7 of 17 with geographic ulcers) responded to idoxuridine therapy. The mean time to corneal re-epithelialization for dendritic ulcers (6 days) and geographic ulcers (7 days) was similar for both therapies.
In other clinical studies, VIROPTIC was evaluated in the treatment of herpes simplex virus keratitis in patients who were unresponsive or intolerant to the topical administration of idoxuridine or vidarabine. VIROPTIC was effective in 138 of 150 (92%) patients (109 of 114 with dendritic and 29 of 36 with geographic ulcers) as evidenced by corneal re-epithelialization. The mean time to corneal re-epithelialization was 6 days for patients with dendritic ulcers and 12 days for patients with geographic ulcers.
The clinical efficacy of VIROPTIC in the treatment of stromal keratitis and uveitis due to herpes simplex virus or ophthalmic infections caused by vacciniavirus and adenovirus has not been established by well-controlled clinical trials. VIROPTIC has not been shown to be effective in the prophylaxis of herpes simplex virus keratoconjunctivitis and epithelial keratitis by well-controlled clinical trials. VIROPTIC is not effective against bacterial, fungal, or chlamydial infections of the cornea or nonviral trophic lesions.
Triple Negative Breast Cancer

# Overview
It is now commonly understood that breast cancer is not one form of cancer, but many different "subtypes" of cancer.  These subtypes of breast cancer are generally diagnosed based upon the presence, or lack of, three "receptors" known to fuel most breast cancers: estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2). The most successful treatments for breast cancer target these receptors.
Unfortunately, none of these receptors are found in women with triple negative breast cancer. A triple negative breast cancer diagnosis means that the offending tumor is estrogen receptor-negative, progesterone receptor-negative and HER2-negative, thus giving rise to the name "triple negative breast cancer." On a positive note, this type of breast cancer is typically responsive to chemotherapy. Because of its triple negative status, however, triple negative tumors generally do not respond to receptor targeted treatments. Depending on the stage of its diagnosis, triple negative breast cancer can be particularly aggressive, and more likely to recur than other subtypes of breast cancer.
Triple negative breast cancer accounts for approximately 15% of all breast cancer cases. It occurs most often in African American and younger women.  Because it is a recently recognized form of breast cancer, there is very little known about its pathology. Thus, there is an urgent need for targeted research and better treatment options for this disease.
Tropomyosin receptor kinase C
Tropomyosin receptor kinase C (TrkC), also known as NT-3 growth factor receptor, neurotrophic tyrosine kinase receptor type 3, or TrkC tyrosine kinase is a protein that in humans is encoded by the NTRK3 gene.
TrkC is the high affinity catalytic receptor for the neurotrophin NT-3 (neurotrophin-3). As such, TrkC mediates the multiple effects of this neurotrophic factor, which includes neuronal differentiation and survival.
The TrkC receptor is part of the large family of receptor tyrosine kinases. A "tyrosine kinase" is an enzyme which is capable of adding a phosphate group to the certain tyrosines on target proteins, or "substrates". A receptor tyrosine kinase is a "tyrosine kinase" which is located at the cellular membrane, and is activated by binding of a ligand via its extracellular domain. Other example of tyrosine kinase receptors include the insulin receptor, the IGF-1 receptor, the MuSK protein receptor, the Vascular Endothelial Growth Factor (or VEGF) receptor, etc. The "substrate" proteins which are phosphorylated by TrkC include PI3 kinase.

# Family members
TrkC is part of a sub-family of protein kinases which includes TrkA and TrkB.  Also, there are other neurotrophic factors structurally related to NT-3: NGF (for Nerve Growth Factor), BDNF (for Brain Derived Neurotrophic Factor) and NT-4 (for Neurotrophin-4). While TrkB mediates the effects of BDNF, NT-4 and NT-3, TrkA is bound and thereby activated only by NGF. Further, TrkC binds and is activated only by NT-3.
TrkB binds BDNF and NT-4 more strongly than it binds NT-3.  TrkC binds NT-3 more strongly than TrkB does.

# Receptor
There is one other NT-3 receptor family besides the Trks (TrkC & TrkB), called the "LNGFR" (for "low affinity nerve growth factor receptor"). As opposed to TrkC, the LNGFR plays a somewhat less clear role in NT-3 biology. Some researchers have shown the LNGFR binds and serves as a "sink" for neurotrophins. Cells which express both the LNGFR and the Trk receptors might therefore have a greater activity - since they have a higher "microconcentration" of the neurotrophin. It has also been shown, however, that the LNGFR may signal a cell to die via apoptosis - so therefore cells expressing the LNGFR in the absence of Trk receptors may die rather than live in the presence of a neurotrophin.

# Role in cancer
Although originally identified as an oncogenic fusion in 1982, only recently has there been a renewed interest in the Trk family as it relates to its role in human cancers because of the identification of NTRK1 (TrkA), NTRK2 (TrkB) and NTRK3 (TrkC) gene fusions and other oncogenic alterations in a number of tumor types. A number of Trk inhibitors are (in 2015) in clinical trials and have shown early promise in shrinking human tumors.

## TrkC (NTRK3 gene) inhibitors in development
Entrectinib (formerly RXDX-101) is an investigational drug developed by Ignyta, Inc., which has potential antitumor activity. It is a selective pan-trk receptor tyrosine kinase inhibitor (TKI) targeting gene fusions in trkA, trkB, and trkC (coded by NTRK1, NTRK2, and NTRK3 genes) that is currently in phase 2 clinical testing.
Tweetbook Author Instructions

# Introduction
Welcome to Tweetbook. Tweetbook was developed with the mission of memorializing interesting peer-reviewed interventional cardiology case reports to facilitate a productive discussion of these cases harnessing the enthusiasm of the twitter cardiology community.

# Topics of Interest
We are looking for case reports related to Interventional Cardiology.  These include:
- Hemodynamics
- Pericardial Disease
- Intravascular
- Imaging and Physiologic Assessment
- Left Main Disease
- Bifurcation Lesions
- Coronary Artery Stenting
- Coronary Atherectomy
- Coronary Thrombectomy
- Chronic Total Occlusions
- Coronary Bypass Graft Intervention
- Spontaneous Coronary Artery Dissection
- Coronary Microvascular Disease
- Coronary Anomalies and Aneurysms
- Percutaneous Valve Therapies
- Congenital heart Disease
- Left Atrial Appendage Occlusion
- Cardiogenic Shock and Mechanical Support Devices
- Peripheral Vascular Disease
- Complications
- Pharmacology
- Acute Coronary Syndromes
- Noninvasive Cardiovascular Imaging
- Miscellaneous

# How to Submit
Case reports should be submitted by email to the editorial office : tweetbook@wikidoc.org for peer review. Please review and adhere to the author instructions below for a quicker response time.

# Author Instructions
Case reports, including imaging studies, or pictures, that illustrate either important "classic" or novel findings or techniques, provide insight into basic mechanisms, emphasize an abnormality, or highlight a potential new technique or role for noninvasive interventions will be considered for publication.
After publication, the clinical case will be tweeted to engage discussion with the authors and the twitter audience. Authors are encouraged to be a part of this process.
On the tweetbook, the written portion of the case should include a title page, descriptive text of no more than two pages, double spaced, in 12 point Times New Roman with up to 5 references and a figure or multimedia legend.
Motion clips may be submitted in .gif format. Images can be in .jpeg, .png, or .tiff format Other media formats will NOT be accepted.

## Title Page
The title page should contain these elements:
- Full title
- Authors names, academic degrees, and affiliations
- Name and complete address for correspondence (include street name and address as well as post office box)
- Twitter account name
- Telephone number, and email address